TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer (NSCLC).
OVERVIEW OF ACTIVITY
Lung cancer is a devastating disease with broad-reaching impact on public health that accounts for 13% of all new cancer cases in the United States and the most cancer-related deaths among both men and women. In 2015 in the United States alone it is estimated that the disease will culminate in 221,200 new cases and 158,040 deaths. Only 17% of all patients with lung cancer are alive 5 years or more after diagnosis, despite currently available therapies. Among the 15% of lung cancer cases diagnosed as early localized disease, 5-year survival rates increase to approximately 55%. Thus, early detection and treatment of lung cancer remain important issues to researchers and clinicians alike as they hold the potential for improvements in outcome. Chemotherapy has been the mainstay systemic therapeutic intervention, often combined with adjunctive radiation therapy among patients with inoperable Stage III disease, and the plethora of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially within the past several years. Development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge, and in addition to the significant strides made in understanding and targeting specific mutations responsible for the pathogenesis of lung cancer, recent insights into how to harness the body’s own immune system are now being applied to the management of this disease.
These video proceedings from the third part of a 5-part integrated CNE curriculum originally held at the 2015 ONS Annual Congress feature discussions with leading lung cancer investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.
PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with lung cancer.
LEARNING OBJECTIVES
- Communicate the clinical relevance of gene mutations and tumor histology to patients with NSCLC.
- Discuss the benefits and risks associated with systemic treatments used in the evidence-based management of metastatic NSCLC, including chemotherapeutic agents, targeted biologic strategies and novel immunotherapies.
- Educate patients about potential side effects associated with commonly employed therapies, and provide preventive and emergent strategies to reduce or ameliorate these toxicities.
- Identify opportunities to enhance the collaborative role of oncology nurses in the comprehensive biopsychosocial care of patients with advanced NSCLC.
ACCREDITATION STATEMENT
CNE credit is no longer available for this issue
CREDIT DESIGNATION STATEMENT
CNE credit is no longer available for this issue
FOR SUCCESSFUL COMPLETION
This is a video CNE program.
CNE credit is no longer available for this issue
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CNE activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a
conflict of interest resolution process:
Julie R Brahmer, MD
Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Paid Research: AstraZeneca Pharmaceuticals LP; Uncompensated Research: Bristol-Myers Squibb Company.
Ann Culkin, RN, OCN
Clinical Nurse
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York
Advisory Committee: Novartis Pharmaceuticals Corporation, TESARO Inc.
Kelly EH Goodwin, MSN, RN, ANP-BC
Thoracic Cancer Center
Massachusetts General Hospital
Boston, Massachusetts
No real or apparent conflicts of interest to disclose.
Anne S Tsao, MD
Associate Professor
Director, Mesothelioma Program
Director, Thoracic Chemo-Radiation Program
The University of Texas MD Anderson Cancer Center
Department of Thoracic/Head and Neck Medical Oncology
Houston, Texas
Advisory Committee: Astellas Scientific and Medical Affairs Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Lilly, MedImmune Inc, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Takeda Oncology; Contracted Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, GlaxoSmithKline, MedImmune Inc, Merck.
MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation and Genentech BioOncology.
Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio
Last review date: August 2015
Expiration date: August 2016
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
